Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Jul 27, 2023; 15(7): 1388-1396
Published online Jul 27, 2023. doi: 10.4240/wjgs.v15.i7.1388
Table 1 Demographic, clinical, procedural and pathological characteristics of patients in the major complication and no major complication groups
Variables
Major complication, n = 10, %
No major complication, n = 1847, %
P value
Sex
    Male8, 80.01100, 59.60.189
    Female2, 20.0747, 40.4
Age, median (Q1, Q3)65.0 (54.5, 76.3)58.0 (47.0, 67.0)0.156
Comorbidity
    Cardiovascular and cerebrovascular diseases2, 20.0238, 12.90.504
    Extensive ascites0, 035, 1.90.660
    Obstructed jaundice3, 30.0137, 7.40.007
Laboratory test
    Platelet count < 50 × 109/L0, 015, 0.80.922
    Prebiopsy hemoglobin level, median (Q1, Q3)112.5 (76.5, 126.3)125.0 (112, 139)0.027
    Fibrinogen < 2 g/L5, 50.0228, 12.3< 0.001
    PT prolonged 5 s1, 10.063, 3.40.255
Objectives of PLB
    Focal liver lesions8, 80.01346, 72.90.336
    Diffuse liver disease2, 20.0501, 27.1
Prebiopsy application of anticoagulants/antiplatelet medication/Y2, 20.079, 4.50.02
Postbiopsy application of hemostatic medication/Y9, 90.0462, 26.6< 0.001
Operator/10-yr experience6, 60.0665, 36.00.115
Biopsy technique
    Bare introduction Tru-cut (18G)6, 60.0922, 49.90.525
    Coaxial introduction Tru-cut (18G)4, 40.0925, 50.1
Location of targets
    Right6, 75.01046, 73.00.659
    Left1, 12.5301, 21.0
    Hilar1, 12.586, 6.0
The maximum diameter of targets, median (Q1, Q3)2.8 (1.7, 6.3)3.3 (2.1, 5.9)0.514
Multilesion/Y4, 44.0848. 60.20.336
Post-biopsy hemoglobin level, median (Q1, Q3)81.0 (65.3, 107.8)114.7 (109.0, 126.0)0.001
Repeat biopsy/Y0, 030, 1.60.685
Number of specimens, median (Q1, Q3)2 (2.0, 2.3)2 (2.0, 2.0)0.553
Histological analysis
    HCC0, 0278, 15.10.094
    ICC3, 30.0222, 12.0
    Secondary hepatic tumor2, 20.0516, 27.9
    Liver abscess1, 10.090, 4.9
    Chronic liver disease0, 0393, 21.3
    Others4, 40.0348, 18.8